Скачать или смотреть 2024 Antibody Engineering & Therapeutics Presentation by Hui Foon Tan, PhD & Stuart A. Sievers, PhD

Speaker 1: Hui Foon Tan, PhD
Title: Global Product Manager, GenScript
Presentation Title: Accelerating Antibody Drug discovery with GenScript’s MonoRab™ & TurboCHO™ platforms
Bio: Hui Foon Tan is a Global Product Manager who currently supports GenScript antibody discovery & production service. She graduated with her Ph.D. in Biological Sciences from Nanyang Technological University, Singapore, and continued to work as a Postdoctoral Research Fellow in cancer research for another two years. After she joined GenScript, Dr. Tan supported proteins and antibody production services in the APAC region for a year. She provides application support for pre- and post-sale activities for services, updates, and seminars to support co-stakeholders, distributors, and customers. Currently, she is supporting the launch of new services and training in antibody production services. She also collates market dynamics and competitive market information from the field to understand global market trends and collaborate with the team.
Abstract: The therapeutic antibody market is rapidly growing due to unmet needs and increased awareness of targeted therapies. The availability of advanced techniques and platforms in the market speeds up the process of antibody drug discovery to meet the increasing demands. GenScript's MonoRab™ and TurboCHO™ platforms streamline development, reducing timelines and costs. This integrated approach delivers high-quality therapeutic antibodies faster, addressing urgent medical needs and advancing biopharmaceutical innovation.

Speaker 2: Stuart A. Sievers, PhD
Title: Senior Director, Discovery Research
Presentation Title: The development of a novel CD8-targeting lipid nanoparticle to transiently engineer CD8+ T cells in vivo using mRNA to express a CD19 CAR
Company: Capstan Therapeutics
Bio: Dr. Stuart Sievers is the Senior Director of Discovery Research at Capstan Therapeutics. His team focuses on antibody and chimeric antigen receptor (CAR) discovery and engineering, supporting the development of targeted lipid nanoparticles to engineer cells in vivo. Previously, Stuart worked at Kite Pharma, directing antibody discovery and CAR screening efforts to support the development of clinical- and commercial-stage cell therapies. Stuart earned his undergraduate degree in Biochemistry from UC Berkeley, his PhD in Biochemistry from UCLA under David Eisenberg, and completed postdoctoral research at Caltech with Pamela Bjorkman. His research has led to publications and patents on a variety of topics, including amyloid fibril formation and inhibition, antibody and CAR design, and novel reagents for CAR detection.
Abstract: Despite the success of ex vivo chimeric antigen receptor (CAR) T cell therapies, challenges in cell manufacturing, scalability, and the need for lymphodepleting chemotherapy highlight the necessity for an off-the-shelf in vivo CAR technology applicable to broader indications. To that aim, we developed CPTX2309, a novel in vivo anti-CD19 CAR mRNA product delivered by a CD8-targeted lipid nanoparticle (tLNP), optimized for pre-clinical performance and advancement to clinical development.